Immune-checkpoint inhibitors targeting PD-1 or PD-L1 have already substantially improved
the outcomes of patients with many types of cancer, although only 20–40% of patients derive …

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …

Immunotherapy with checkpoint inhibitors is well established as an effective treatment for
non-small cell lung cancer and melanoma. The list of approved indications for treatment with …

The recent development of immune checkpoint inhibitors (ICIs) has led to promising
advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic …

In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors …

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option
for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor …

Immunotherapy, including use of checkpoint inhibitors against PD-1, PD-L1, and CTLA-4,
forms the backbone of oncologic management for the majority of non-small cell lung …

With an escalating number of predictive biomarkers emerging in non–small cell lung
carcinoma (NSCLC), immunohistochemistry (IHC) is being used as a rapid and cost …

Abstract Background PD-L1 immunohistochemistry (IHC) testing is usually carried out on
tissue blocks from core needle biopsy or surgical resections. In this study, we assessed the …

Abstract In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society
of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in …